PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

• Sagar Lonial,
• Hang Quach,
• Meletios A. Dimopoulos,
• Paula Rodríguez-Otero,
• Jesus Berdeja,
• Paul Richardson,
• Margee Kyada,
• Shuyu Chu,
• Min Chen,
• Patricia Abad,
• Juliane Morando,
• Niels W.C.J. van de Donk

Affiliations

Sagar Lonial

1 Winship Cancer Institute, Emory University, Atlanta, United States

Hang Quach

2 St Vincent’s Hospital, University of Melbourne, Melbourne, Australia

Meletios A. Dimopoulos

3 National and Kapodistrian University of Athens, Athens, Greece

Paula Rodríguez-Otero

4 Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain

Jesus Berdeja

5 Sarah Cannon Research Institute, Nashville, United States

Paul Richardson

6 Dana-Farber Cancer Institute, Boston, United States

Margee Kyada

7 Bristol Myers Squibb, Princeton, United States

Shuyu Chu

7 Bristol Myers Squibb, Princeton, United States

Min Chen

7 Bristol Myers Squibb, Princeton, United States

Patricia Abad

7 Bristol Myers Squibb, Princeton, United States

Juliane Morando

7 Bristol Myers Squibb, Princeton, United States

Niels W.C.J. van de Donk

8 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands